"Crepey" is a beauty-counter word, not a diagnosis, and that matters for what can be said about it. It describes skin that has gone thin and finely wrinkled, like crepe paper — most often on the upper arms, the inner thighs, the knees, the backs of the hands and the neck. This page sets out what the word refers to in the medical literature, counts the trials that have measured it, and checks where peptides come in. It does not recommend a product.
If the concern is surplus, sagging skin after weight loss, that is a different question with different trials, covered on our peptides for loose skin page. For firmness claims more generally, see peptides for skin tightening.
What crepey skin is
Two features sit behind the word. The dermis — the collagen and elastin layer under the surface — gets thinner, and the elastic fibres in it are damaged or lost, so the surface folds into fine, criss-cross lines when the skin is pinched or moved. Sun exposure drives much of the elastic-fibre damage, which is why the backs of the hands and the forearms crepe earlier than skin that stays covered.
At its far end the same process has a medical name: dermatoporosis, chronically fragile, atrophic skin that bruises, tears and heals poorly, described in the literature by analogy with osteoporosis. PubMed holds 68 records using that term as of 2 November 2026, most about older adults and skin tears. Two 2026 cream trials framed their "mature, crepey skin" participants with it, which is the clearest sign of where the cosmetic word and the medical one overlap. Our elastin peptides page covers why adult skin barely replaces lost elastin, which is the part of the problem a cream would have to address.
The trials that measured crepey skin
A PubMed search on 2 November 2026 for crepey, crêpey or crepe-like returned 14 records. Several are eyelid-surgery and blepharoplasty papers using the word descriptively; a 1964 paper treated "fine crepey wrinkles" with dermabrasion and peels. Four carry the randomized-controlled-trial tag, and two more are trials without it:
| Study | Product tested | Design | Who was involved | Peptides? |
|---|---|---|---|---|
| Rawlings et al., J Cosmet Dermatol 2013 (PMID 23438139) | vitamin A palmitate and antioxidant oil | randomized, grader-blinded, vs no treatment, 12 weeks, face and body | first author's affiliation is a consultancy; sponsor not stated in the abstract | none named |
| Kavali et al., Aesthet Surg J 2021 (PMID 32462206) | a topical body-firming moisturizer | randomized, double-blind, split-body vs placebo moisturizer, 40 women, upper arms, 12 weeks | one listed affiliation is a contract-research firm; the abstract names no product | none named |
| Wang et al., J Cosmet Dermatol 2026 (PMID 41981821) | a body-firming serum | randomized, double-blind, split-body vs vehicle; 11 people on thighs, 12 on hands | funded by Allergan Aesthetics; four authors are employees | "plant extracts and peptides," none named |
| Ablon et al., J Drugs Dermatol 2026 (PMID 42696337) | a centella and mandelic acid cream (Galderma) | randomized, blinded in-use study, knees and thighs, 12 weeks | the product is the maker's | none named |
| Ablon et al., J Drugs Dermatol 2026 (PMID 42826145) | the same cream, five biopsied participants | not randomized | same authors | none named |
| Draelos et al., J Cosmet Dermatol 2026 (PMID 42117281) | a 13-adaptogen serum for menopausal skin | open-label, no control, 16 weeks | one author is an employee of the brand | participants had to stop topical peptides first |
Three things follow from the table.
- No trial tests a named peptide on crepey skin. The only formula said to contain peptides does not say which, and it was tested on 23 people by the company that sells it.
- Every product is a multi-ingredient formula. The trials can say a cream changed graded crepiness; they cannot say which ingredient did.
- The comparisons are weak where they exist. The strongest designs are split-body against a vehicle or placebo, which controls for the moisturizing effect of the base. Even there, in the Allergan body-serum trial the vehicle side also improved from baseline on texture, firmness and crepiness on some sites, which is what moisturizing alone does.
The peptide trial that did test something
One randomized trial has put collagen peptides to the test in thin, fragile skin. Guadanhim and colleagues in São Paulo enrolled 56 postmenopausal women aged 60 to 93 with stage I dermatoporosis on the forearms and randomized them, in a factorial design, to oral hydrolyzed collagen (5 g a day) or placebo, and to a 2.5% topical collagen serum or placebo, for six months (Dermatology and Therapy, 2023, PMID 36547800). The result was flat: no difference for either product, or the two together, on clinical scores, quality of life, skin elasticity, thickness or echogenicity, or on biopsy markers. The authors concluded that oral or topical collagen peptides "should not be used routinely" in that population.
It is one trial, in older women with a measurable skin-fragility diagnosis, and it tested collagen hydrolysate rather than the signal peptides (palmitoyl pentapeptide-4 and the like) sold in serums. But it is the only randomized peptide trial on this kind of skin, and it is negative. For how collagen peptides and signal peptides differ, see peptides vs collagen.
What can fairly be said
- Crepey skin is real and has a mechanism: a thinner dermis and damaged elastic fibres, much of it from the sun.
- Body creams have been tested against it in small, mostly sponsored, 12-week trials, with investigator-graded improvements; none isolates a peptide.
- The one randomized peptide trial in fragile, thinning skin found nothing.
- What is not established is whether any topical peptide changes crepey skin, how long any cream's effect lasts, or whether it is more than hydration. Sun damage can be prevented going forward; what is already there is a question for a dermatologist, who can also check for causes such as long-term steroid use.
Sources
Opened 2 November 2026: PubMed E-utilities searches "crepey"[tiab] OR "crepe-like"[tiab] OR "crêpey"[tiab] (14 records, every title read) and dermatoporosis[tiab] (68 records). Abstracts: Rawlings AV et al., J Cosmet Dermatol 2013, PMID 23438139; Kavali CM et al., Aesthet Surg J 2021, PMID 32462206; Wang JV et al., J Cosmet Dermatol 2026, PMID 41981821 (funding and ingredient description from the PMC full text, PMC13080057); Ablon G et al., J Drugs Dermatol 2026, PMIDs 42696337 and 42826145; Draelos ZD et al., J Cosmet Dermatol 2026, PMID 42117281 (washout criteria from PMC13162087); Guadanhim LRS et al., Dermatol Ther (Heidelb) 2023, PMID 36547800. Corrections go to the contact page.